Core Viewpoint - Micron Heart Technology-B (02160.HK) has reported significant growth in the adoption of its VitaFow® series transcatheter aortic valves and delivery systems (TAVI), with a projected increase in implant volume for 2025 [1] Group 1: Product Performance - The VitaFow® series TAVI has been introduced in 35 countries and regions globally, with a cumulative implant volume nearing 1,300 cases [1] - The implant volume for 2025 is expected to exceed 850 cases, representing a nearly 350% increase compared to 2024 [1] - In the second half of 2025, the implant volume is anticipated to grow by over 170% compared to the first half, driven by the commercialization of VitaFow Liberty® following CE certification in European countries [1] Group 2: Market Expansion - The company is focusing on expanding its market share in emerging markets in Asia and Latin America, contributing to the anticipated growth in implant volumes [1]
微创心通-B(02160.HK)TAVI产品年植入量增长近350%